Arcus Biosciences (RCUS) Misses Q4 EPS by 6c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.08), $0.06 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $31 million versus the consensus estimate of $29.03 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Progress Software completes $400M acquisition of Domo's data platform
• Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy